“Conclusions Taken together, the use of glucosamine as an adjuvant in meloxicam therapy may be caused by the synergistic mechanism of meloxicam for the attenuation of OA development through systemically reducing IL-1ß.”
“IL-1ß levels also showed a significant decrease after administering a combination of glucosamine and meloxicam (p < 0.01).”